Thomas Gießmann

2.2k total citations
33 papers, 1.9k citations indexed

About

Thomas Gießmann is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Thomas Gießmann has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pharmacology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Thomas Gießmann's work include Drug Transport and Resistance Mechanisms (15 papers), Pharmacogenetics and Drug Metabolism (9 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Thomas Gießmann is often cited by papers focused on Drug Transport and Resistance Mechanisms (15 papers), Pharmacogenetics and Drug Metabolism (9 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Thomas Gießmann collaborates with scholars based in Germany, United States and Japan. Thomas Gießmann's co-authors include Werner Siegmund, Werner Weitschies, Hubert Mönnikes, Norbert Hosten, Carsten Schiller, R Warzok, Peter Dazert, Christiane Modeß, Heyo K. Kroemer and Eike Schroeder and has published in prestigious journals such as Annals of the Rheumatic Diseases, American Journal of Physiology-Endocrinology and Metabolism and Pharmaceutical Research.

In The Last Decade

Thomas Gießmann

33 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Gießmann Germany	19	817	511	480	379	246	33	1.9k
Yoshiyuki Shirasaka Japan	29	1.4k 1.7×	659 1.3×	188 0.4×	569 1.5×	549 2.2×	83	2.4k
Hiroyasu Ogata Japan	24	432 0.5×	245 0.5×	383 0.8×	307 0.8×	259 1.1×	100	1.7k
Sibylle Neuhoff United Kingdom	30	1.6k 1.9×	794 1.6×	404 0.8×	968 2.6×	503 2.0×	68	2.8k
Klaus Kutz Switzerland	21	304 0.4×	434 0.8×	347 0.7×	141 0.4×	297 1.2×	59	1.8k
Henning Blume Germany	25	168 0.2×	249 0.5×	492 1.0×	278 0.7×	338 1.4×	89	2.1k
Kazuhiko Arimori Japan	22	547 0.7×	241 0.5×	226 0.5×	433 1.1×	380 1.5×	96	1.6k
Jeannine M. Fisher United States	15	759 0.9×	380 0.7×	105 0.2×	901 2.4×	232 0.9×	18	1.6k
Kirstin Thelen Germany	20	324 0.4×	259 0.5×	248 0.5×	386 1.0×	191 0.8×	26	1.3k
Phyllissa Schmiedlin‐Ren United States	19	1.3k 1.6×	739 1.4×	105 0.2×	1.3k 3.3×	354 1.4×	31	2.5k
Jin‐ding Huang Taiwan	21	779 1.0×	351 0.7×	138 0.3×	1.0k 2.7×	468 1.9×	61	1.9k

Countries citing papers authored by Thomas Gießmann

Since Specialization

Citations

This map shows the geographic impact of Thomas Gießmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Gießmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Gießmann more than expected).

Fields of papers citing papers by Thomas Gießmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Gießmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Gießmann. The network helps show where Thomas Gießmann may publish in the future.

Co-authorship network of co-authors of Thomas Gießmann

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Gießmann. A scholar is included among the top collaborators of Thomas Gießmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Gießmann. Thomas Gießmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wong, Diane, et al.. (2024). Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials. Naunyn-Schmiedeberg s Archives of Pharmacology. 397(10). 8101–8116. 3 indexed citations

Abrahamsson, Bertil, Patrick Augustijns, Thomas Gießmann, et al.. (2022). Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. Pharmaceutics. 14(4). 801–801. 10 indexed citations

Wiebe, Sabrina, Thomas Gießmann, Kathrin Hohl, et al.. (2020). Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clinical Pharmacokinetics. 59(12). 1627–1639. 45 indexed citations

Stopfer, Peter, Thomas Gießmann, Kathrin Hohl, et al.. (2017). Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. European Journal of Drug Metabolism and Pharmacokinetics. 43(1). 69–80. 27 indexed citations

Müller, Christian P., et al.. (2012). Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. European Journal of Clinical Pharmacology. 68(11). 1473–1481. 2 indexed citations

Graefe‐Mody, Ulrike, et al.. (2011). A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects. Clinical Therapeutics. 33(8). 1096–1103. 20 indexed citations

May, Karen, Kristin Westphal, Thomas Gießmann, et al.. (2008). Disposition and Antimuscarinic Effects of the Urinary Bladder Spasmolytics Propiverine: Influence of Dosage Forms and Circadian‐Time Rhythms. The Journal of Clinical Pharmacology. 48(5). 570–579. 12 indexed citations

May, Karen, Thomas Gießmann, Danilo Wegner, et al.. (2008). Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. European Journal of Clinical Pharmacology. 64(11). 1085–1092. 13 indexed citations

Garbacz, Grzegorz, Ralph‐Steven Wedemeyer, Stefan Nagel, et al.. (2008). Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. European Journal of Pharmaceutics and Biopharmaceutics. 70(2). 421–428. 140 indexed citations

10.

Oswald, Stefan, Jörg König, Dieter Lütjohann, et al.. (2008). Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenetics and Genomics. 18(7). 559–568. 79 indexed citations

11.

Hermann, Róbert, Werner Siegmund, Thomas Gießmann, et al.. (2007). The Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide. The Journal of Clinical Pharmacology. 47(8). 1005–1013. 18 indexed citations

12.

Gießmann, Thomas, Christiane Modeß, Danilo Wegner, et al.. (2006). Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. British Journal of Clinical Pharmacology. 61(4). 440–450. 35 indexed citations

13.

Oswald, Stefan, Thomas Gießmann, Danilo Wegner, et al.. (2006). Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clinical Pharmacology & Therapeutics. 80(5). 477–485. 37 indexed citations

14.

Oswald, Stefan, Sierk Haenisch, Thomas Sudhop, et al.. (2006). Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clinical Pharmacology & Therapeutics. 79(3). 206–217. 90 indexed citations

15.

Bethke, T.D., Thomas Gießmann, Kristin Westphal, et al.. (2006). Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 44(11). 572–579. 18 indexed citations

16.

Schiller, Carsten, Thomas Gießmann, Werner Siegmund, et al.. (2005). Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Alimentary Pharmacology & Therapeutics. 22(10). 971–979. 479 indexed citations

17.

Gießmann, Thomas, K. May, Christiane Modeß, et al.. (2004). Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clinical Pharmacology & Therapeutics. 76(3). 192–200. 146 indexed citations

18.

Gießmann, Thomas, Christiane Modeß, M Zschiesche, et al.. (2004). CYP2D6genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clinical Pharmacology & Therapeutics. 75(3). 213–222. 110 indexed citations

19.

Freyse, Ernst‐Joachim, Thomas Gießmann, Klaus J. Petzke, et al.. (2003). Effects of fatty acids on hepatic amino acid catabolism and fibrinogen synthesis in young healthy volunteers. American Journal of Physiology-Endocrinology and Metabolism. 285(1). E54–E62. 5 indexed citations

20.

Gießmann, Thomas, et al.. (1998). Schnittkanten nach lamellärer Keratotomie mit verschiedenen Mikrokeratomen. Klinische Monatsblätter für Augenheilkunde. 213(11). 293–300. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact